DexCom stock: buy or sell?

DXCM stock price: $208.37 2.74% At close on November 15th, 2019

Updated on:
November 15th, 2019


After climbing to all-time highs several times in past weeks, DexCom jumped 2.74% to $208.37. On November 7th DXCM skyrocketed an astounding 21.36%.

DexCom, Inc., a medical device company, together with its subsidiaries, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally.

Should I buy DexCom stock?

Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Trading strategies are meant for helping you in the decision process of what stocks to choose and when is the best moment to buy them. At, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

Currently, 2 buy setups match with DexCom stock right now:

Buy setupElegible
New all-time highYes
New 52 week highYes
Price crossing up 200d MANo
100d MA crossing up 200d MANo

Is DexCom stock a buy?

Banks and financial institutions publish stock ratings everyday. At, we gathered 15 ratings published for DXCM stock in the last 30 days.

The general sentiment of these ratings is bullish for DXCM stock, with 11 positive ratings.
Is DXCM a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-9-3BMO Capital Marketsn/aOutperform
2019-8-29Robert W. Bairdn/aOutperform
2019-8-1UBS Groupn/aNeutral
2019-8-1Robert W. Bairdn/aOutperform
2019-8-1Raymond Jamesn/aOutperform
2019-8-1JPMorgan Chase & Co.n/aOverweight
2019-8-1Canaccord Genuityn/aBuy
2019-8-1BTIG Researchn/aHold
2019-8-1Bank of American/aBuy
2019-6-6Northland Securitiesn/aHold
2019-5-2Raymond JamesOutperformOutperform
2019-4-30UBS GroupNeutralNeutral
2019-2-22Canaccord Genuityn/aBuy

DexCom stock analysis

Daily outlook

DexCom closed yesterday at $208.37 after marking a new all time high ($208.38) and jumped a very good 2.74%.

DexCom shares touched new all time highs again yesterday, setting highs to $208.38. Shares ended at $208.37 and jumped 2.74%. On August, SMA100d and SMA200d crossed up triggering a rise of 23.82%. From a daily perspective, DXCM is in a short term uptrend after plotting its last bottom ($150.41, on Nov/5) higher than the previous bottom, and its last top ($208.20, on Tuesday) also over the previous top. Now trading in between its last bottom and last top DXCM might consolidate in a plain range, waiting to break out over $208.20 or down under $150.41. On November 7th DXCM price bounced up over the SMA of 100 days demonstrating to be a significant support for this stock.

DXCM stock chart (daily)

Weekly outlook

DexCom skyrocketed 5.19% this week and set a new all time high at $208.38. Last week DXCM climbed an exceptional 20.59% in just one week. Late October DXCM plunged a scary -6.47% in just one week. This week was the 3rd green week in a row.

If you observe the weekly chart, price finally broke over the resistance at $162.14 and continued climbing. Since SMA20d and SMA40w crossed up by mid August, DXCM price climbed $52.93 per share (34.05%). Since price and SMA40w lines crossed up by mid June, DXCM climbed $82.39 (65.40%).

DXCM stock chart (weekly)

DexCom stock price history

DexCom IPO was on April 14th, 2005 at $12.08 per share1. Since then, DXCM stock grew a 1,624.90%, with a yearly average of 116.10%. If you had invested right after DXCM's IPO a $1,000 in DexCom stock in 2005, it would worth $16,249.00 today.

1: Adjusted price after possible price splits or reverse-splits.

DexCom stock historical price chart

DXCM stock reached all-time highs yesterday with a price of $208.38.

DexCom stock price target is $170.60

How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. We detected 14 price predictions for DXCM stock released in the last 30 days:
DXCM stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-9-3BMO Capital MarketsRaises Target$180.00$190.005.6%
2019-8-29Robert W. BairdRaises Target$186.00$195.004.8%
2019-8-1UBS GroupRaises Target$140.00$160.0014.3%
2019-8-1Robert W. BairdRaises Target$180.00$186.003.3%
2019-8-1Raymond JamesRaises Target$150.00$172.0014.7%
2019-8-1JPMorgan Chase & Co.Raises Target$170.00$190.0011.8%
2019-8-1Canaccord GenuityReiterates$160.00$185.0015.6%
2019-8-1Bank of AmericaRaises Target$162.00$185.0014.2%
2019-6-6Northland SecuritiesReiteratesn/a$125.00-
2019-5-2Raymond JamesLowers Target$160.00$150.00-6.3%
2019-4-30UBS GroupLowers Target$150.00$140.00-6.7%
2019-2-22CowenRaises Target$150.00$175.0016.7%
2019-2-22Canaccord GenuityReiterates$140.00$160.0014.3%
(in average)$159.80$170.607.0%
Moving in a range from $195.00 and $125.00, the price forecast for DXCM stock is $170.60. In average, analysts' outlook on DXCM price target is positive, improving the target by a 7.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

DexCom presented super good results for 2018-Q4 on February. DexCom rocketed Earnings per Share (EPS) by 237.50%, beating experts estimates of $0.16. DexCom posted $0.54.
DXCM earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

Compared to 2017, last anual turnover report draw an amazing increase of 43.58% to $1,031.60 M dollars. Nonetheless, its profit margin (compared to revenues) slipped to -12.32%, that is $-127.10 million.

DXCM annual Sales and Income evolution
2013$160 M-$-29.80 M-18.6%-
2014$259 M62.00%$-22.40 M-8.6%-24.83%
2015$402 M55.09%$-57.60 M-14.3%157.14%
2016$573 M42.61%$-65.60 M-11.4%13.89%
2017$719 M25.33%$-50.20 M-7.0%-23.48%
2018$1,032 M43.58%$-127.10 M-12.3%153.19%

Quarterly financial results

DexCom reported $338.00 million in revenues for 2018-Q4, a 26.73% improvement compared to previous quarter. Reported quarter income marked $-179.70 million with a profit margin of -53.17%. Profit margin plunged a -70.64% compared to previous quarter when profit margin was 17.47%. When comparing sales to same quarter last year, DexCom sales marked an outstanding gain and skyrocketed a 52.94%. Looking back to recent quarterly results, DexCom posted 3 positive quarters in a row.
DXCM quarterly Sales and Income evolution
2017-Q2$171 M-$2.90 M1.7%-
2017-Q3$185 M8.21%$-2.00 M-1.1%-168.97%
2017-Q4$221 M19.72%$-9.40 M-4.3%370.00%
2018-Q1$184 M-16.56%$-24.20 M-13.1%157.45%
2018-Q2$243 M31.51%$30.20 M12.5%-224.79%
2018-Q3$267 M9.98%$46.60 M17.5%54.30%
2018-Q4$338 M26.73%$-179.70 M-53.2%-485.62%
2019-Q1$281 M-17.01%$-26.90 M-9.6%-85.03%

DexCom ownership

When you are planning to invest in a company, it's worth to have a look its ownership structure.

DexCom shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 1.14% of all shares.

Bearish positions for DXCM stock account 0.00%, no big difference from last month.

For a better context understanding, the next table shows ownership data compared to other related companies:

Market cap$19.1 B$151.7 B$67.0 B$51.2 B$354.9 B
Total shares91.5 M1,770.0 M270.0 M208.6 M2,630.0 M
Float shares90.3 M1,760.0 M269.9 M207.1 M2,630.0 M
  - Institutional holdings (%)100.2%76.5%87.5%0.0%69.2%
  - Insider holdings (%)1.1%0.7%0.3%3.9%0.1%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

DexCom summary

Friday, November 15th, 2019
Day range$202.02 - $208.38
Previous close$202.81
Session gain2.74%
Average true range$9.38
50d mov avg$159.71
100d mov avg$158.17
200d mov avg$144.80
Daily patternlt06a
Weekly pattern lb01c

DexCom performance

Stocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. We picked , Becton, Dickinson and, Edwards Lifesciences, , Medtronic, Quidel, Tandem Diabetes Care and West Pharmaceutical Services as the bechmarking frame for DexCom stock.
BDXBecton, Dickinson...0.29%9.41%2.18%
EWEdwards Lifescien...11.99%41.89%57.75%
TNDMTandem Diabetes C...9.38%-4.26%91.91%
WSTWest Pharmaceutic...3.63%29.28%37.02%

DexCom competitors

We chose a few stocks to conform a list of DexCom competitors to watch if you are interested in investing in DXCM:

Latest DexCom stock news